Catch up on Neola Medical’s Q2 2025 highlights, including the successful enrollment of the first preterm born baby in the clinical pilot study in Sweden and advancing preparations for the pivotal U.S. clinical study.
CEO Hanna Sjöström shares insights into these key milestones, recent patent progress, and our strengthened U.S. presence as we continue to advance toward FDA market authorization. CFO David Folkesson presents the financial results for Q2 2025.
Watch the full report presentation and stay for the Q&A session. Tune in here:
https://www.youtube.com/watch?v=CJwJ4gyVyPY